Lincoln Pharma.

Which are the latest news on Lincoln Pharma.?

Why is Lincoln Pharmaceuticals Ltd falling/rising?

As of 05-Sep, Lincoln Pharmaceuticals Ltd's stock is experiencing a decline of 0.67% after three days of gains, with reduced investor participation. Despite this short-term drop, the stock has strong long-term performance, including a year-to-date increase of 28.05%.

As of 05-Sep, Lincoln Pharmaceuticals Ltd's stock price is currently falling, with a change of -4.15, representing a decrease of 0.67%. This decline follows three consecutive days of gains, indicating a trend reversal. The stock's performance today is described as inline with the sector, but it has shown a decrease in investor participation, with a delivery volume that has fallen by 11.96% compared to the 5-day average. <BR><BR>Despite the current drop, the stock has demonstrated strong performance over various periods, including a year-to-date increase of 28.05% and a 1-year return of 12.59%, significantly outperforming the broader market, which has seen a decline of 10.21% over the same period. The stock is also trading above its shorter-term moving averages, although it is below the 100-day moving average, which may indicate some volatility.<BR><BR>The company's financial health is solid, being net-debt free, and it has reported positive results in its latest quarterly performance, with key metrics at their highest levels. However, the recent decline in stock price could be attributed to a combination of profit-taking after previous gains and reduced trading activity among investors. Overall, while the stock is currently experiencing a fall, its long-term performance remains strong relative to market benchmarks.

Who are in the management team of Lincoln Pharma.?

The management team of Lincoln Pharma includes Chairman Kishorbhai M Shah, Managing Director Mahendra G Patel, and several Whole-time Directors, along with Independent Directors and a Company Secretary. They collectively oversee the company's operations and strategic direction.

The management team of Lincoln Pharma includes the following individuals:<BR><BR>1. **Kishorbhai M Shah** - Chairman (Non-Executive)<BR>2. **Mahendra G Patel** - Managing Director<BR>3. **Hasmukhbhai I Patel** - Whole-time Director<BR>4. **Munjal Mahendrabhai Patel** - Whole-time Director<BR>5. **Aashish R Patel** - Whole-time Director<BR>6. **Anand Arvindbhai Patel** - Whole-time Director<BR>7. **Pirabhai R Suthar** - Independent Director<BR>8. **Meha Patel** - Independent Director<BR>9. **Saurin J Parikh** - Independent Director<BR>10. **Rajnikant G Patel** - Director<BR>11. **Trusha Shah** - Company Secretary & Compliance Officer<BR><BR>This team oversees the operations and strategic direction of the company. If you need more specific information about any of the members or their roles, feel free to ask!

What does Lincoln Pharma. do?

Lincoln Pharmaceuticals Ltd manufactures and trades pharmaceutical products, categorized as a Micro Cap company with a market cap of INR 1,234 Cr. As of June 2026, it reported net sales of 177 Cr and a net profit of 36 Cr.

Overview: <BR>Lincoln Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceutical products within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in January 1979 as a Partnership Firm and was converted into a Public Limited Company in January 1995. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 177 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 36 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,234 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 13.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.29% <BR>Debt-Equity: -0.31 <BR>Return on Equity: 11.60% <BR>Price to Book: 1.63 <BR><BR>Contact Details: <BR>Address: Lincoln House B/H Satyam Compe, Science City Road Sola Ahmedabad Gujarat : 380060 <BR>Tel: 91-079-67778000 <BR>Email: info@lincolnpharma.com <BR>Website: http://www.lincolnpharma.com

Who are the peers of the Lincoln Pharma.?

Lincoln Pharma's peers include Jagsonpal Pharma, Amrutanjan Health, Fermenta Biotec, and others. In terms of performance, Fermenta Biotec leads with a 57.50% return, while Lincoln Pharma has a 12.64% return, higher than Amrutanjan Health's -26.26%.

Peers: The peers of Lincoln Pharma are Jagsonpal Pharma, Amrutanjan Healt, Fermenta Biotec., Sigachi Indust., Themis Medicare, Bajaj Healthcare, Kopran, Bharat Parenter., Accent Microcell, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt, Sigachi Indust., Accent Microcell, and the rest have Average management risk. Growth is rated as Good for Accent Microcell and Average for Jagsonpal Pharma, Fermenta Biotec., Sigachi Indust., Lincoln Pharma, Themis Medicare, Bajaj Healthcare, Kopran, and the rest, while Amrutanjan Healt and Bharat Parenter. are rated Below Average. Capital Structure is Excellent for Jagsonpal Pharma, Amrutanjan Healt, Sigachi Indust., Lincoln Pharma, and Accent Microcell, while Good is noted for Kopran, and the rest have Below Average ratings.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fermenta Biotec. at 57.50%, while Amrutanjan Healt has the lowest at -26.26%. Lincoln Pharma's 1-year return is 12.64%, which is higher than Amrutanjan Healt but lower than Fermenta Biotec. Additionally, Bajaj Healthcare and Amrutanjan Healt have negative six-month returns.

How big is Lincoln Pharma.?

As of 31st August, Lincoln Pharmaceuticals Ltd has a market capitalization of 1,234.00 Cr, with recent net sales of 694.24 Cr and a net profit of 96.44 Cr. Shareholder's funds are 671.67 Cr and total assets amount to 797.01 Cr.

As of 31st August, Lincoln Pharmaceuticals Ltd has a market capitalization of 1,234.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Lincoln Pharmaceuticals reported Net Sales of 694.24 Cr and a Net Profit of 96.44 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 671.67 Cr and Total Assets of 797.01 Cr.

Should I buy, sell or hold Lincoln Pharmaceuticals Ltd?

Are Lincoln Pharmaceuticals Ltd latest results good or bad?

Lincoln Pharmaceuticals Ltd's latest results are mixed; while net sales increased by 11.36% year-on-year to ₹187.28 crores, net profit fell by 59.34% from the previous quarter, raising concerns about profitability and operational efficiency. Investors should remain cautious as the company faces challenges despite revenue growth.

Lincoln Pharmaceuticals Ltd's latest results present a mixed picture. In Q4 FY26, the company achieved a net profit of ₹11.63 crores, which is a slight increase of 0.43% year-on-year. However, this figure represents a significant decline of 59.34% compared to the previous quarter, which raises concerns about profitability.<BR><BR>On the positive side, net sales grew by 11.36% year-on-year, reaching ₹187.28 crores, indicating strong revenue momentum driven by domestic demand and exports. However, the operating margin decreased to 13.27%, down 262 basis points from the previous year, reflecting rising input costs and operational challenges.<BR><BR>Overall, while Lincoln Pharmaceuticals showed resilience in revenue growth, the substantial drop in net profit and margin compression suggest underlying issues that need to be addressed. Investors should be cautious and monitor the company's ability to improve profitability and operational efficiency in the coming quarters.

When is the next results date for Lincoln Pharmaceuticals Ltd?

The next results date for Lincoln Pharmaceuticals Ltd is 13 August 2026.

The next results date for Lincoln Pharmaceuticals Ltd is scheduled for 13 August 2026.

Is Lincoln Pharma. technically bullish or bearish?

As of November 20, 2025, Lincoln Pharma's technical outlook is bearish, driven by bearish daily moving averages and KST indicators, despite a mildly bullish signal from Dow Theory on the weekly chart.

As of 20 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include the daily moving averages, which are bearish, and the KST on both weekly and monthly time frames, which are also bearish. The monthly Bollinger Bands indicate a mildly bearish trend, while the Dow Theory shows a mildly bullish signal on the weekly but remains bearish on the monthly. Overall, the combination of these indicators suggests a bearish outlook for Lincoln Pharma.

How has been the historical performance of Lincoln Pharma.?

Lincoln Pharma has shown consistent growth in net sales and profits, with net sales increasing from 366.15 Cr in March 2019 to 623.23 Cr in March 2025, and operating profit rising from 72.87 Cr to 123.97 Cr during the same period, despite some fluctuations in profit margins. Total assets and liabilities have also significantly increased, reflecting robust overall growth.

Answer:<BR>The historical performance of Lincoln Pharma shows a consistent growth trajectory in net sales and profit over the years.<BR><BR>Breakdown:<BR>Lincoln Pharma's net sales have increased from 366.15 Cr in March 2019 to 623.23 Cr in March 2025, reflecting a steady upward trend. Total operating income has followed a similar pattern, rising from 366.15 Cr to 623.23 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, from 298.91 Cr in March 2019 to 521.74 Cr in March 2025. Despite this increase in expenses, operating profit (PBDIT) has shown resilience, climbing from 72.87 Cr to 123.97 Cr, although it peaked at 134.33 Cr in March 2024. Profit before tax reached 109.19 Cr in March 2025, down from 122.24 Cr in March 2024, while profit after tax was 82.35 Cr in March 2025, a decrease from 93.30 Cr in the previous year. The company's total assets have significantly increased from 389.39 Cr in March 2020 to 797.01 Cr in March 2025, indicating robust growth in its asset base. Total liabilities also rose from 389.39 Cr to 797.01 Cr over the same period. Cash flow from operating activities improved to 93.00 Cr in March 2025, up from 63.00 Cr in March 2024, contributing to a net cash inflow of 7.00 Cr in March 2025. Overall, Lincoln Pharma has demonstrated a solid performance with increasing revenues and profits, despite some fluctuations in profit margins and expenses.

Who are the top shareholders of the Lincoln Pharma.?

The top shareholders of Lincoln Pharma include promoter Munjal Mahendrabhai Patel with 13.37%, individual investors at 36.27%, and 53 foreign institutional investors holding 5.14%. The highest public shareholder is Kishor M. Shah with 2.39%.

The top shareholders of Lincoln Pharma include the promoters, who are the majority shareholders. The promoter with the highest holding is Munjal Mahendrabhai Patel, owning 13.37% of the company. Additionally, individual investors hold a significant portion at 36.27%. In terms of institutional investment, 53 foreign institutional investors (FIIs) collectively hold 5.14%, while mutual funds have a minimal presence with holdings from 2 schemes at 0.0%. The highest public shareholder is Kishor M. Shah, who holds 2.39%.

Is Lincoln Pharma. overvalued or undervalued?

As of May 26, 2025, Lincoln Pharma is considered an attractive investment, assessed as undervalued with a PE Ratio of 13.92, an EV to EBITDA of 9.36, and a ROCE of 18.63%, significantly lower than peers like Sun Pharma and Divi's Lab, indicating strong growth potential despite recent stock performance declines.

As of 26 May 2025, the valuation grade for Lincoln Pharma has moved from very attractive to attractive. The company is currently assessed as undervalued. Key ratios include a PE Ratio of 13.92, an EV to EBITDA of 9.36, and a ROCE of 18.63%. <BR><BR>In comparison to its peers, Lincoln Pharma's PE Ratio is significantly lower than Sun Pharma's 35.25 and Divi's Lab's 79.33, indicating a more favorable valuation. Additionally, while Lincoln Pharma has a PEG Ratio of 0.00, suggesting strong growth potential relative to its price, competitors like Cipla and Dr. Reddy's Labs have PEG Ratios of 0.97 and 14.54, respectively. Despite a recent decline in stock performance year-to-date, Lincoln Pharma has outperformed the Sensex over a three-year period, reinforcing its potential as an undervalued investment in the pharmaceuticals sector.

Has Lincoln Pharma. declared dividend?

Yes, Lincoln Pharmaceuticals Ltd has declared a 15% dividend, amounting to 1.5 per share, with an ex-date of September 15, 2023. While recent total returns show volatility, longer-term performance over five years has been positive, with a total return of 247.97%.

Lincoln Pharmaceuticals Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 15 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -37.95%, the dividend return was 0%, resulting in a total return of -37.95%.<BR><BR>Over the past year, the price return was -2.18%, the dividend return was 0%, leading to a total return of -2.18%.<BR><BR>In the 2-year period, the price return was 51.57%, the dividend return was 0.37%, culminating in a total return of 51.94%.<BR><BR>For the 3-year period, the price return was 98.05%, the dividend return was 1.06%, resulting in a total return of 99.11%.<BR><BR>In the last 4 years, the price return was 96.75%, the dividend return was 1.42%, leading to a total return of 98.17%.<BR><BR>Finally, over the past 5 years, the price return was 245.19%, the dividend return was 2.78%, resulting in a total return of 247.97%.<BR><BR>Overall, while Lincoln Pharmaceuticals has declared a dividend, the recent total returns indicate significant volatility, particularly in the short term, with negative returns over the last 6 months and 1 year. However, the longer-term returns show a more positive trend, especially over the 5-year period.